Search for: "ACTAVIS, INC."
Results 101 - 120
of 382
Sorted by Relevance
|
Sort by Date
13 Nov 2017, 7:00 am
Actavis, Inc., 2017 Cal. [read post]
11 Oct 2013, 9:34 pm
Meuth, Associate General Counsel, Intellectual Property for Eisai Inc.; Kelly L. [read post]
25 Feb 2020, 9:03 am
Actavis Laboratories UT, Inc., with Judges Newman, O’Malley, Stoll and Lourie dissenting. [read post]
27 Feb 2013, 9:41 pm
Actavis Inc. et al. [read post]
21 Feb 2016, 8:07 pm
Actavis Laboratories UT, Inc. v. [read post]
27 Aug 2017, 10:01 pm
Actavis, Inc. [read post]
27 Aug 2017, 10:01 pm
Actavis, Inc. [read post]
15 Aug 2019, 11:16 am
Actavis Laboratories FL, Inc. [read post]
17 Jun 2013, 9:34 am
Actavis, Inc. [read post]
23 Mar 2016, 9:38 am
Actavis, Inc., 2016 WL 1090356, No. 12-cv-7591 (D.N.J. [read post]
15 Mar 2010, 6:03 pm
Actavis, Inc., 2010 WL 46513 (C.A. 5 (La.). [read post]
8 Nov 2017, 7:26 am
Actavis, Inc., et al, No. [read post]
18 Dec 2009, 9:59 am
Actavis Group, Actavis Pharma Manufacturing Pvt Ltd. and Actavis, Inc. [read post]
28 Aug 2014, 7:28 am
" Depomed, Inc. v. [read post]
5 Dec 2017, 7:21 am
Actavis Laboratories UT, Inc. et al, 3-17-cv-01076 (TXND November 17, 2017, Order) (Lynn, USDJ) [read post]
12 Aug 2020, 9:59 pm
Actavis, Inc. (2013)"). [read post]
12 Apr 2017, 10:32 am
Defendants are Actavis LLC of Parsippany, New Jersey; Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania; and Teva Pharmaceutical Industries, Ltd. of Petach Tikva, Israel. [read post]
12 Apr 2017, 10:32 am
Defendants are Actavis LLC of Parsippany, New Jersey; Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania; and Teva Pharmaceutical Industries, Ltd. of Petach Tikva, Israel. [read post]
5 Sep 2016, 12:27 pm
Actavis Laboratories FL, Inc., Civil Action No. 15-164-LPS (D.Del. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
